MassMutual Private Wealth & Trust’s Revance Therapeutics, Inc. RVNC Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-183	Closed	-$1.61K	–	2142
2023 Q4	$1.61K	Buy	183 +44	+32%	+$360	﹤0.01%	1576
2023 Q3	$1.59K	Buy	139 +25	+22%	+$481	﹤0.01%	1563
2023 Q2	$2.88K	Hold	114	–	–	﹤0.01%	1371
2023 Q1	$3.67K	Hold	114	–	–	﹤0.01%	1228
2022 Q4	$2K	Sell	114 -15	-12%	-$343	﹤0.01%	1359
2022 Q3	$3K	Buy	+129	New	+$2.62K	﹤0.01%	1146
2022 Q1	–	Sell	-36	Closed	-$1K	–	1664
2021 Q4	$1K	Buy	+36	New	+$600	﹤0.01%	1346

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MassMutual Private Wealth & Trust's RVNC Position: Q1 2024 in Review

MassMutual Private Wealth & Trust sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 183 shares — an estimated $1.61K sold.

MassMutual Private Wealth & Trust first reported a position in RVNC in Q4 2021 and held it in 7 quarters. The position peaked at $3.67K in Q1 2023. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

MassMutual Private Wealth & Trust reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
MassMutual Private Wealth & Trust sold 183 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $1.61K.
MassMutual Private Wealth & Trust first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 7 quarters.
MassMutual Private Wealth & Trust's Revance Therapeutics, Inc. position peaked at $3.67K in Q1 2023.
188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on MassMutual Private Wealth & Trust's 13F filing for Q1 2024, filed 9 Apr 2024.